Macrophage-colony stimulating factor (CSF1) predicts breast cancer progression and mortality

Anticancer Research

Volumn 35, Issue 2, 2015, Pages 865-874

  Richardsen, Elin ^a,b   Uglehus, Rebecca Dale ^a   Johnsen, Stein Harald ^a,b   Busund, Lill Tove ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Breast cancer; CSF1; CSF1R; Epithelial tumor cells; Metastases; T lymphocytes; Tumor stromal cells; Tumor infiltrating macrophages

Indexed keywords

CD68 ANTIGEN; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR 1 RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYSIS; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST EPITHELIUM; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CLINICAL ARTICLE; DIGITAL VIDEO ANALYSIS; EPITHELIUM TUMOR; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL; TUMOR ASSOCIATED LEUKOCYTE; VERY ELDERLY; BREAST TUMOR; DISEASE COURSE; FEMALE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 84923683928     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Pollard JW: Trophic macrophages in development and disease. Nat Rev Immunol 9: 259-270, 2009.
2. Campell MJ, Toonlar NY, Garwood ER, Huo D, Moore DH, Kramtsov AL, Au A, Chen Y, Malaka DO, Lin A, Adeyanju OO, Li S, Gong C, McGrath M, Olopack OI and Essermann LJ: Proliferating macrophages associated with high grade hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat 128(3): 703-711, 2011.
3. Bingle L, Brown NJ and Lewis CE: The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196: 254-265, 2002.
4. Qian BZ and Pollard JW: Macrophage diversity enhances tumor progression and metastasis. Cell 141: 39-51, 2010.
5. Pixley F and Stanley ER: CSF-1 regulation of the wandering macrophage: Complexity in action. Trends Cell Biol 14(11): 628-638, 2004.
6. Ide H, Hatake K, Terado Y, Tsukino H, Okegawa T, Okegawa T, Nutahara K, Higashihara E and Horie SH: Serum level of macrophage colony-stimulating factor is increased in prostate cancer patients with bone metastasis. Hum Cell 21(1): 1-6, 2008.
7. Stanley ER, Berg KL, Einstein DB, Lee PS, Pixley FJ, Wang Y and Yeung YG: Biology and action of colony-stimulating factor-1. Mol Reprod Dev 46(1): 4-10, 1997.
8. Fretiér S, Besse A, Delwail A, Garcia M, Morel F, leprivey-Lorgeot V, Wijdenes J, Praloran V and Lecron JC: Cyclosporin A inhibition of macrophage colony-stimulating factor (M-CSF) production be activated human T Lymphocytes. J Leucoc Biol 71(2): 289-294, 2002.
9. Hume DA: The mononuclear phagocyte system. Curr opin Immunol 18(1): 49-53, 2006.
10. Pollard JW: Tumor-educated macrophages promote tumor progression and metastasis. Nat Rev Cancer 4(1): 71-78, 2004.
11. Condeelis J and Pollard JW: Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124(2): 263-266, 2006.
12. Dermaria S, Volm MD, Shapiro RL, Yee HT, Oratz R, Formenti SC and Muggia F: Development of tumor-infiltrating lymhocytes in breast cancer after neoadjuvant Paclitaxel chemotherapy. Clin cancer Res 7(10): 3025-3030, 2001.
13. Denkert C, Loibl S, Roller M, Muller BM, Komor M, udczies J, Darb-Esfahani S; Kronenwett R, Hanusch C, von Torne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M and von Minckwitz G: Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28: 105-113, 2010.
14. Loi S1, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, de Azambuja E, Quinaux E, Di Leo A, Michiels S, Piccart MJ and Sotiriou C: Prognostic and predicitive value of tumor-infiltrating lymphocytes in phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31(7): 860-867, 2013.
15. Ham M and Moon A: Inflammatory and microenvironmental factors involved in breast cancer progression. Arch Pharm Res 36(12): 1419-1431, 2013.
16. Pollard JW: Macrophages define the invasive microenviroment in breast cancer. J Leucocyte Biol 84(3): 623-630, 2008.
17. Toy EP and Azodi M: Enhanced ovarian cancer tumorigenesis and metastasis by the macrophage colony-stimulating factor. Neoplasia 11(1): 136-144, 2009.
18. Richardsen E, Uglehus RD, Due J, Busch and Busund LT: The prognostic impact of M-CSF, CSF-1R, CD68 and CD3 in prostatic carcinoma. Histopathology 53(1): 30-38, 2008.
19. Lewis CE and Pollard JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res 66(2): 605-612, 2006.
20. Sapi E: The role of CSF-1 in normal physiology of mammary gland and breast cancer. Exp Biol Med 229(1): 1-11, 2004.
21. Kacinski BM, Scata KA, Carter D, Yee LD, Sapi E, King BL, Chambers SK, Jones MA, Pirro MH and Stanley ER: FMS (CSF-1R) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro. Oncogene 6(6): 941-952, 1991.
22. Tamimi RM, Brugge JS, Freedman ML, Miron A, Iglehart JD, Colditz GA and Hankinson SE: Circulating colony stimulating factor-1 of mammary gland and breast cancer. Cancer Res 68(1): 18-21, 2008.
23. Lin EY and Pollard JW: Role of infiltrated leucocytes in tumor growth and spread. Br J Cancer 90(11): 2053-2058, 2004.
24. Barrios CH, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, Pivot X, Iwata H, Aogi K, Lugo-Quintana R, Harbeck N, Brickman MJ, Zhang K, Kern KA and Martin M: Phase III study of bevacicumab plus docetaxel compared with placebo plus docetaxel for first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 10; 28(20): 3239-3227, 2010.
25. Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, Zhao YW, and Wei YQ: Prognostic significance of tumor-associated macrophages in solid tumor: A meta-analysis of the literature. PLoS ONE 7(12): e50946, 2012.
26. World Health Organizations: Tumors of the Breast and female Genital Organs. ISBN 92 832 24124, 2003.
27. World Health Organizations: TMN - classification of Malignant Tumors. 6th ed, UICC, ISBN 0 471 22288 7, 2002.
28. Elston CW and Ellis IO: Pathologic prognostic factors in breast cancer. I. The value of histological grades in breast cancer. Experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991.
29. Aharinejad S, Salama M, Paulus P, Zins K, Berger A and Singer CF: Elevated CSF1 serum concentration predicts poor overall survival in women with early breast cancer. Endocr Relat Cancer 14; 20(6):777-783, 2013.
30. Tang RP, Kacinski B, Validire P, Beuvon F, Sastre X, Benoit P, dela Rochefordière A, Mosseri V, Pouillart P and Scholl S: Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoietic growth factor release by tumor cells. J Cell Biochem 44(3): 189-198, 1990.
31. Beck AH, Espinosa I, Edris B, Li R, Montgomery K, Zhu S, Varma S, Marinelli RJ, van de Rijn M and West RB: The macrophage colony-stimulating factor 1 response signature in breast carcinoma. Clin Ca Res 15(3): 778-787, 2009.
32. Lin EY, Gouon-Evans V, Nguyen AV and Pollard JW: The macrophage growth factor csf-1 in mammary gland development and tumor progression. J Mammary Gland Biol Neoplasia 7(2): 147-162, 2002.
33. Maher MG, Sapi E, Turner B, Gumbs A, Perotta PL, Carter D, Kacinski BM and Haffty BG: Prognostic significance of colony-stimulating factor receptor expression in ipsilateral breast recurrence. Clin Cancer Res 4(8): 1851-1856, 1998.
34. Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M, Earl HM, Poole CJ, Hiller L, Dunn JA, Bowden SJ, Twelves C, Bartlett JM, Mahmoud SM, Rakha E, Ellis IO, Liu S, Gao D, Nielsen TO, Pharoah PD and Caldas C: Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol 25(8): 1536-1543, 2014.
35. Qian BZ and Pollard JW: New tricks for metastasis-associated macrophages. Breast Cancer Res 14(4): 316, 2012.
36. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA and Pollard JW: CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475(7355): 222-2225, 2011.
37. Qian B, Deng Y, Im JH, Muschel RJ, Zou Y, Li J, Lang RA and Pollard JW: A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS ONE 4: e6562, 2009.
38. Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, Squadrito ML, Segura I, Li X, Knevels E, Costa S, Vinckier S, Dresselaer T, Åkerud P, De Mol M, Salomäki H, Phillipson M, Wyns S, Larsson E, Buysschaert I, Botling J, Himmelreich U, Van Ginderachter JA, De Palma M, Dewerchin M, Claesson-Welsh L, and Carmeliet P: HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19: 31-44, 2011.
39. De Boer WI, Hiemstra PS, Sont JK, De Heer E, Rabe KF, Van Krieken JH and Sterk PJ: Image analysis and quantification in lung tissue. Clin Exp Allergy 31(3): 504-508, 2001.
40. Faul JL, Demers EA, Burke CM and Poulter LW: The reproducibility of repeated measures of airway inflammation in stable atopic asthma. Am J Respir Crit Care Med 160(5 Pt 1): 1457-1461, 1999.